Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors

Journal of Clinical Oncology

Volumn 30, Issue 13, 2012, Pages 1527-1533

  Infante, Jeffrey R ^a   Camidge, D Ross ^b   Mileshkin, Linda R ^c   Chen, Eric X ^d   Hicks, Rodney J ^c   Rischin, Danny ^c   Fingert, Howard ^e   Pierce, Kristen J ^e   Xu, Huiping ^e   Roberts, W Gregory ^e   Shreeve, S Martin ^e   Burris, Howard A ^a   Siu, Lillian L ^d  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; MIDAZOLAM; PF 562271; ANTINEOPLASTIC AGENT; CYP3A PROTEIN, HUMAN; CYTOCHROME P450 3A; DIAGNOSTIC AGENT; ENZYME INHIBITOR; FOCAL ADHESION KINASE 1; FOCAL ADHESION KINASE 2; PF-00562271; PROTEIN KINASE INHIBITOR; PTK2 PROTEIN, HUMAN; PTK2B PROTEIN, HUMAN; PYRIMIDINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; SULFONAMIDE;

ADULT; ADVANCED SOLID TUMOR; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; DEHYDRATION; DIARRHEA; DIET RESTRICTION; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG SAFETY; DYSGEUSIA; EDEMA; FATIGUE; FEMALE; FOOD; HEADACHE; HUMAN; HYPERTENSION; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; NAUSEA; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRESYNCOPE; PRIORITY JOURNAL; PROTEINURIA; SOLID TUMOR; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING; AUSTRALIA; CANADA; CANCER STAGING; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG ANTAGONISM; ENZYMOLOGY; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY; NEOPLASM; NONLINEAR SYSTEM; PATHOLOGY; SCINTISCANNING; TREATMENT OUTCOME; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AUSTRALIA; CANADA; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FEMALE; FLUORODEOXYGLUCOSE F18; FOCAL ADHESION KINASE 1; FOCAL ADHESION KINASE 2; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDAZOLAM; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; NEOPLASMS; NONLINEAR DYNAMICS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RADIOPHARMACEUTICALS; SULFONAMIDES; TREATMENT OUTCOME; UNITED STATES;

EID: 84862990976     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.38.9346     Document Type: Article

References (25)

1. Frisch SM, Vuori K, Ruoslahti E, et al: Control of adhesion-dependent cell survival by focal adhesion kinase. J Cell Biol 134:793-799, 1996 (Pubitemid 26269148)
2. McLean GW, Carragher NO, Avizienyte E, et al: The role of focal-adhesion kinase in cancer: A new therapeutic opportunity. Nat Rev Cancer 5:505-515, 2005 (Pubitemid 40942827)
3. Sieg DJ, Hauck CR, Ilic D, et al: FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol 2:249-256, 2000
4. Fujii T, Koshikawa K, Nomoto S, et al: Focal adhesion kinase is overexpressed in hepatocellular carcinoma and can be served as an independent prognostic factor. J Hepatol 41:104-111, 2004 (Pubitemid 39005160)
5. Imaizumi M, Nishimura M, Takeuchi S, et al: Role of tyrosine specific phosphorylation of cellular proteins, especially EGF receptor and p125FAK in human lung cancer cells. Lung Cancer 17:69-84, 1997 (Pubitemid 27261493)
6. Itoh S, Maeda T, Shimada M, et al: Role of expression of focal adhesion kinase in progression of hepatocellular carcinoma. Clin Cancer Res 10:2812-2817, 2004 (Pubitemid 38509160)
7. Miyazaki T, Kato H, Nakajima M, et al: FAK over-expression is correlated with tumour invasiveness and lymph node metastasis in oesophageal squamous cell carcinoma. Br J Cancer 89:140-145, 2003 (Pubitemid 36903212)
8. Rodrigo JP, Dominguez F, Suarez V, et al: Focal adhesion kinase and E-cadherin as markers for nodal metastasis in laryngeal cancer. Arch Otolaryngol Head Neck Surg 133:145-150, 2007 (Pubitemid 46294115)
9. Sood AK, Armaiz-Pena GN, Halder J, et al: Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest 120:1515-1523, 2010
10. Sun CK, Ng KT, Sun BS, et al: The significance of proline-rich tyrosine kinase2 (Pyk2) on hepatocellular carcinoma progression and recurrence. Br J Cancer 97:50-57, 2007 (Pubitemid 47012087)
11. Smith CS, Golubovskaya VM, Peck E, et al: Effect of focal adhesion kinase (FAK) downregulation with FAK antisense oligonucleotides and 5-fluorouracil on the viability of melanoma cell lines. Melanoma Res 15:357-362, 2005 (Pubitemid 41558945)
12. Wu ZM, Yuan XH, Jiang PC, et al: Antisense oligonucleodes targeting the focal adhesion kinase inhibit proliferation, induce apoptosis and cooperate with cytotoxic drugs in human glioma cells. J Neurooncol 77:117-123, 2006
13. Shen TL, Park AY, Alcaraz A, et al: Conditional knockout of focal adhesion kinase in endothelial cells reveals its role in angiogenesis and vascular development in late embryogenesis. J Cell Biol 169:941-952, 2005 (Pubitemid 41002870)
14. Buckbinder L, Crawford DT, Qi H, et al: Proline-rich tyrosine kinase 2 regulates osteoprogenitor cells and bone formation, and offers an anabolic treatment approach for osteoporosis. Proc Natl Acad Sci U S A 104:10619-10624, 2007 (Pubitemid 47185714)
15. Guinamard R, Okigaki M, Schlessinger J, et al: Absence of marginal zone B cells in Pyk-2-deficient mice defines their role in the humoral response. Nat Immunol 1:31-36, 2000
16. Ling S, Sheng JZ, Braun AP: The calcium-dependent activity of large-conductance, calciumactivated K+ channels is enhanced by Pyk2- and Hck-induced tyrosine phosphorylation. Am J Physiol Cell Physiol 287:C698-C706, 2004 (Pubitemid 39095856)
17. Okigaki M, Davis C, Falasca M, et al: Pyk2 regulates multiple signaling events crucial for macrophage morphology and migration. Proc Natl Acad Sci U S A 100:10740-10745, 2003 (Pubitemid 37140098)
18. Fan H, Guan J-L: Compensatory function of Pyk2 protein in the promotion of focal adhesion kinase (FAK)-null mammary cancer stem cell tumor-igenicity and metastatic activity. J Biol Chem 286:18573-18582, 2011
19. Roberts WG, Ung E, Whalen P, et al: Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Res 68:1935-1944, 2008 (Pubitemid 351416580)
20. Ucar DA, Hochwald SN: FAK and interacting proteins as therapeutic targets in pancreatic cancer. Anticancer Agents Med Chem 10:742-746, 2010
21. Johnson TR, Khandrika L, Kumar B, et al: Focal adhesion kinase controls aggressive phenotype of androgen-independent prostate cancer. Mol Cancer Res 6:1639-1648, 2008
22. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
23. Young H, Baum R, Cremerius U, et al: Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: Review and 1999 EORTC recommendations: European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 35:1773-1782, 1999 (Pubitemid 29512308)
24. Siesser PM, Hanks SK: The signaling and biological implications of FAK overexpression in cancer. Clin Cancer Res 12:3233-3237, 2006
25. Poulikakos PI, Xiao GH, Gallagher R, et al: Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK. Oncogene 25:5960-5968, 2006 (Pubitemid 44477290)